Neuren Pharmaceuticals (NURPF) Stock Price, News & Analysis

Company Overview

Neuren Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing treatments for neurodevelopmental disorders and other conditions affecting the central nervous system. The company’s research is centered on therapies intended to address significant unmet medical needs in children and adults.

Neuren’s lead product, trofinetide, was developed for Rett syndrome and received approval from the U.S. Food and Drug Administration in 2023 under the brand name Daybue. Neuren licensed development and commercial rights for trofinetide in North America to Acadia Pharmaceuticals, which markets the therapy in the United States. Neuren may receive royalties and other payments under its agreement with Acadia.

The company is also developing NNZ-2591, an investigational therapy being studied for several rare neurodevelopmental conditions, including Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome. Neuren conducts or supports research through clinical development programs in the United States and Australia, with commercialization activities for trofinetide handled through its North American partnership.

Key Stats

• Today's Range: C$14.28 to C$14.28
• 50-Day Range: C$13.46 to C$17.00
• 52-Week Range: C$7.70 to C$17.25
• Volume: N/A
• Average Volume: 1,604 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:NURPF
• CIK: N/A
• Web: www.neurenpharma.com
• Phone: (139) 092-0480
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A